Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News New technology threatens patented drugs

New technology threatens patented drugs

24th November 2005

A change in intellectual property law will allow companies to develop versions of patented drugs without infringing any patents, according to In-Pharma Technologist.com.

UK drug firm Accentus will use the CrystalGEM crystallisation technology to research generic versions of drugs which are currently patented. The system reduces the time in which crystallisation can take place, allowing researchers to find polymorphisms much quicker than usual.

Accentus will take advantage of the EU’s “Bolar provision,” which allows the research and development of generic versions of drugs which are under patent protection. It said that other firms were already interested in the technology.

“With CrystalGEM, viable crystallisations have been achieved in over 80 per cent of predicted conditions, compared to 5 to 10 per cent with high throughput methods,” Dr George Tranter, director of CrystalGEM developer Chiralabs, who licensed the technology to Accentus, told In-Pharma Technologist.

Accentus said that other firms were interested in taking advantage of the technoogy. “We have already been approached by several companies in this regard,” said David Hipkiss, general manger of C3 Technology at Accentus.

The technology is cheaper than high-throughput methods, often costing less than ?50,000 for a full screen.

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.